News Chart Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 21:00:00 26/06/2026 BST			5-day change	1st Jan Change
3.040 ^USD	+1.33%		+3.05%	+10.55%

06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

c8f08dc28d67dae59b9c95191e.uZdYI6wdY2F_ZtCwUQ35TLnY2FKuqYT14Vg2ezrdDWk._OYIdf1HUSw-MorYaUSfBPOoiBDg7tuX1msPEG7rWQv30x181VoEIic_iQ~0173067d71c8fa0fdaf56adefd67c254